Physician Participation
Participating in the
Observational Registry
This document describes how physician participation in the MyoGuard Protocol observational registry works — including physician workflow, patient experience, data governance, and consent architecture.
Study Design
Observational, Non-Interventional
The registry collects observational data generated through routine clinical use of the MyoGuard Protocol CDS platform. No experimental intervention is introduced. Patient assessments are completed as part of the standard physician-led clinical workflow.
The SRI framework is designed to support prospective evaluation through this observational infrastructure. Longitudinal assessment data — collected across a patient's GLP-1 treatment course — enables cohort-level trajectory analysis when aggregated at the registry level.
Study type: Prospective observational registry · Intervention: None — standard CDS use only · Population: GLP-1-treated adult patients
Physician Workflow
How Physician Participation Works
- 01
Register and receive your referral credentials
Physicians register with MyoGuard Protocol and receive a unique referral slug and activation link. These credentials attribute patient assessments to your cohort within the registry.
- 02
Share the activation link with eligible patients
Eligible patients — those receiving or being considered for GLP-1 receptor agonist therapy — are invited to complete an SRI assessment via your physician activation link. No account creation is required for the initial assessment.
- 03
Patient completes consent and assessment
Patients who wish to participate in the observational registry provide explicit informed consent during the assessment process. Consent is versioned and stored independently of clinical CDS records. Patients who decline research consent continue through the standard clinical workflow.
- 04
Longitudinal assessment data builds over time
Repeat assessments — completed during routine follow-up consultations — accumulate longitudinal data within your cohort. This trajectory data forms the analytical basis for future observational evaluation.
Patient Experience
What Patients Experience
Patients complete a structured SRI assessment covering GLP-1 medication details, current body metrics, activity level, and symptomatic indicators. No laboratory values or imaging data are required at this stage.
Consent to research participation is presented clearly and distinctly from the clinical CDS workflow.
Patients may decline research participation and continue to receive CDS outputs through the standard clinical flow.
Patients may withdraw consent at any time. Withdrawal triggers data suppression across all future cohort exports.
No patient-identifiable data is included in any research export or cohort analysis.
Data Governance
Three-Layer Data Architecture
Clinical CDS, observational research infrastructure, and de-identified export are maintained as architecturally distinct layers. PHI does not cross the clinical-to-research boundary.
Layer 1 — Clinical CDS
Assessment data, SRI outputs, protocol plans. PHI present. Physician and patient access only. Never exported to the research layer.
Layer 2 — Observational Research Infrastructure
De-identified cohort records. Patient identifier replaced by a pseudonymous research participant ID. Physician attribution retained for cohort grouping.
Layer 3 — De-identified Export
Aggregate CSV pipeline for cohort-level analysis. A thirteen-field PHI exclusion set is enforced at export. An audit trail is maintained for all export operations.
Consent Architecture
Informed Consent Design
Explicit and separate consent capture
Research consent is collected as a distinct step, separate from the clinical CDS workflow. Patients cannot inadvertently enrol through routine assessment completion.
Versioned consent records
Each consent event is recorded with a consent version, timestamp, and patient identifier. If the consent document is updated, patients are required to re-consent before continued research participation.
Right to withdraw
Patients retain the right to withdraw at any time. Withdrawal is processed immediately and triggers data suppression in all subsequent cohort exports.
Audit trail
All consent events — grant, update, and withdrawal — are recorded in an auditable event log maintained independently of the clinical CDS record.
Express Interest
Physician Registration
Physicians who wish to contribute to the observational registry are invited to register through the MyoGuard Protocol physician portal. Following registration, an activation link and referral credentials are generated for patient attribution.
For institutional enquiries, partnership discussions, or academic collaboration, contact hello@myoguard.health.
Classification: Physician-led Clinical Decision Support (CDS). The Sarcopenia Risk Index (SRI) is an expert-consensus framework and is not currently a validated clinical instrument. The SRI framework is designed to support prospective evaluation through this observational infrastructure. All intellectual property is held by Meridian Wellness Systems LLC, Wyoming, USA. Provisional patent application pending.